Gene expression profiling in chronic lymphocytic leukaemia

Codony, Carles; Crespo, Marta; Abrisqueta, Pau; Montserrat, Emili; Bosch, Francesc

doi:10.1016/j.beha.2009.05.006

« Previous Next »Best Practice & Research Clinical Haematology
Volume 22, Issue 2 , Pages 211-222, June 2009

Gene expression profiling in chronic lymphocytic leukaemia

Carles Codony, PhD (Research Assistant)
- Department of Hematology and Laboratory of Experimental Hematology, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
Marta Crespo, PhD (Research Assistant)
- Institute of Cancer Genetics, Columbia University, New York, New York 10032, USA
Pau Abrisqueta, MD (Resident in Haemathology)
- Department of Hematology and Laboratory of Experimental Hematology, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
Emili Montserrat, MD, PhD (Professor of Medicine)
- Department of Hematology and Laboratory of Experimental Hematology, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
Francesc Bosch, MD, PhD (Assistant Professor of Medicine)
- Department of Hematology and Laboratory of Experimental Hematology, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
- Corresponding author. Tel.: +34 932 275 475; Fax: +34 932 275 484.

The proliferation of new techniques that allow a multiparametric study of gene expression, the mutational state of genomic DNA, DNA methylation and the phosphorylation of receptor and adaptor proteins has led to an increased understanding of the origin of different cancers, the definition of new prognosis markers and the response to treatment profiles. Gene profiling studies on chronic lymphocytic leukaemia (CLL) are at the origin of new prognosis markers such as zeta-associated protein-70 (ZAP-70), LPL and CLLU1, which, at present, are under study for their application to clinical practice. An increased resolution in the mutational state at genomic level has underscored the importance of deletion 13q14 at the origin of CLL and 13q and 17p in response to treatment. Some new insights regarding changes in gene expression in CLL cells depending on the microenvironment have been described, but more work is yet to be done in the field.

Keywords: chronic lymphocytic leukaemia, gene profiling, ZAP-70, miR-15, LPL, CLLU1, PEG10, del13q14